AngioDynamics
This article was originally published in The Gray Sheet
Executive Summary
Full-scale launch of the AngioStent for treatment of malignant biliary strictures is planned for this summer following FDA clearance, announced Feb. 8. The E-Z EM subsidiary currently has 19 sales reps and will begin test marketing in 30-45 days